ResMed (RMD) Q1 Earnings and Revenues Beat Estimates

Core Insights - ResMed reported quarterly earnings of $2.55 per share, exceeding the Zacks Consensus Estimate of $2.49 per share, and showing an increase from $2.20 per share a year ago, resulting in an earnings surprise of +2.41% [1] - The company achieved revenues of $1.34 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.94% and up from $1.22 billion year-over-year [2] - ResMed has consistently surpassed consensus EPS and revenue estimates over the last four quarters [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $2.65 on revenues of $1.39 billion, and for the current fiscal year, it is $10.75 on revenues of $5.56 billion [7] - The earnings outlook will be influenced by management's commentary during the earnings call, which is crucial for assessing future stock performance [3][4] Industry Context - The Medical - Products industry, to which ResMed belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment [5] Stock Performance - ResMed shares have increased approximately 10.9% since the beginning of the year, while the S&P 500 has gained 17.2%, indicating underperformance relative to the broader market [3] - The current Zacks Rank for ResMed is 3 (Hold), suggesting that the stock is expected to perform in line with the market in the near future [6]